<DOC>
	<DOCNO>NCT00532727</DOCNO>
	<brief_summary>The purpose study determine whether great activity carboplatin taxane standard care ( docetaxel ) woman ER- , PR- HER2- breast cancer . The trial aim recruit 370 450 patient .</brief_summary>
	<brief_title>Triple Negative Breast Cancer Trial</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm ER , PR , primary breast cancer Histologically confirm HER2 primary breast cancer Measurable confirm metastatic recurrent locally advanced disease unsuitable local therapy suitable taxane chemotherapy Patients stable , treat bain metastasis eligible provide informed consent give sit measurable disease present . Patients bone metastasis currently receive bisphosphonates palliation eligible providing informed consent give sit measurable disease present ECOG Performance Status 0 , 1 , 2 Adequate haematology , biochemical index ( FBC , U &amp; Es ) LFTs = Normal bilirubin , AST and/or ALT = 3 x ULN Alk Phos &gt; 5 x ULN ( isolated elevation AST/ALT â‰¤5 x ULN Adequate renal function Creatinine clearance &gt; 25mls per minute Written inform consent , able comply treatment follow Original primary tumour subsequent relapse know positive ER , PR , HER2 receptors Patients unfit chemotherapy neuropathy &gt; grade 1 ( sensory motor ) Known allergy platinum compound mannitol Known sensitivity taxanes Patients inoperable locally advanced disease suitable local radiotherapy anthracycline contain regimen Previous chemotherapy metastatic disease anthracycline inclusion criterion Previous exposure taxane adjuvant chemotherapy within 12 month trial entry Previous treatment taxane recurrent locally advanced disease Previous treatment platinum chemotherapy drug LFTs = Abnormal bilirubin ( &gt; ULN ) , AST and/or ALT &gt; 3 X ULN Alk Phos &gt; 5 x ULN ( isolated elevation AST/ALT &gt; 5 x ULN ) Patients life expectancy le 3 month Previous malignancy adequately treat situ carcinoma uterine cervix basal squamous call carcinoma skin , unless disease free interval least 10 year Previous synchronous second breast cancer ( unless also confirm ER , PR HER2 ) Patients bone limited disease Other serious uncontrolled medical condition concurrent medical illness likely compromise life expectancy and/or completion trial therapy Pregnant , lactate potentially childbearing woman use adequate contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Triple Negative</keyword>
</DOC>